PART I Item 1. B usiness. Overview We are a biopharmaceutical company that historically was focused on developing a portfolio of small molecule superoxide dismutase (SOD) mimetics to improve radiotherapy in cancer, primarily by reducing one of the most common side effects of radiotherapy, severe oral mucositis (SOM). In October 2025 we sold our assets related to avasopasem and rucosopasem and all other dismutase mimetics assets to Biossil, Inc. (Biossil), a privately-held company based in Toront...
Q2 FY2026 — expected 2026-09-06
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-19 | 2025-12-31 | 0001563577-26-000005 | EDGAR | 67K words |
| 2025-03-31 | 2024-12-31 | 0000950170-25-047798 | EDGAR | — |
| 2024-03-28 | 2023-12-31 | 0000950170-24-037614 | EDGAR | — |
| 2023-03-08 | 2022-12-31 | 0000950170-23-006588 | EDGAR | — |
| 2022-03-10 | 2021-12-31 | 0000950170-22-003292 | EDGAR | — |
| 2021-03-11 | 2020-12-31 | 0001564590-21-012244 | EDGAR | — |
| 2020-03-10 | 2019-12-31 | 0001564590-20-009542 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001193125-25-278816 | EDGAR | 19K words |
| 2025-08-13 | 2025-06-30 | 0000950170-25-107616 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0000950170-25-071956 | EDGAR | — |
| 2024-12-13 | 2024-09-30 | 0001193125-24-277849 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0000950170-24-096654 | EDGAR | — |
| 2024-05-13 | 2024-03-31 | 0000950170-24-058197 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0000950170-23-063361 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0000950170-23-042058 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-020842 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0000950170-22-023516 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0000950170-22-015753 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0000950170-22-009950 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-03 | 0001193125-26-141187 | EDGAR | 1K words |
| 2026-02-18 | 0001193125-26-055919 | EDGAR | — |
| 2026-02-12 | 0001193125-26-048696 | EDGAR | — |
| 2025-10-27 | 0001193125-25-250698 | EDGAR | — |
| 2025-10-21 | 0001193125-25-245093 | EDGAR | — |
| 2025-09-03 | 0001193125-25-194948 | EDGAR | — |
| 2025-04-02 | 0001193125-25-071428 | EDGAR | — |
| 2025-02-25 | 0001193125-25-035114 | EDGAR | — |
| 2024-12-31 | 0001193125-24-287073 | EDGAR | — |
| 2024-12-20 | 0001193125-24-283187 | EDGAR | — |
104 total filings indexed. 75 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001563577 |
| Ticker | GRTX |
| Exchange | OTC |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report